A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer

Lung Cancer

Volumn 99, Issue , 2016, Pages 23-30

  Pietanza, M Catherine ^a   Litvak, Anya M ^a   Varghese, Anna M ^a   Krug, Lee M ^a   Fleisher, Martin ^a   Teitcher, Jerrold B ^a   Holodny, Andrei I ^a   Sima, Cami S ^a   Woo, Kaitlin M ^a   Ng, Kenneth K ^a   Won, Helen H ^a   Berger, Michael F ^a   Kris, Mark G ^a   Rudin, Charles M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Circulating tumor cells; Hedgehog inhibitor; Hedgehog pathway; LDE225; Small cell lung cancer; SOX2 amplification

Indexed keywords

CISPLATIN; CREATINE KINASE; ETOPOSIDE; SONIDEGIB; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; PYRIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRY SKIN; DYSGEUSIA; FATIGUE; FEMALE; HEARING IMPAIRMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; KARNOFSKY PERFORMANCE STATUS; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYALGIA; NEUTROPENIA; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SMALL CELL LUNG CANCER; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; LUNG TUMOR; MORTALITY; PATHOLOGY; TREATMENT OUTCOME; TUMOR EMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIPHENYL COMPOUNDS; CISPLATIN; ETOPOSIDE; FEMALE; HEDGEHOG PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PYRIDINES; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84975795342     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.04.014     Document Type: Article

References (33)

1. [1] Pepicelli, C.V., Lewis, P.M., McMahon, A.P., Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr. Biol. 8 (1998), 1083–1086.
2. [2] Liu, H., Kho, A.T., Kohane, I.S., Sun, Y., Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development. PLoS Med., 3, 2006, e232.
3. [3] Watkins, D.N., Berman, D.M., Burkholder, S.G., Wang, B., Beachy, P.A., Baylin, S.B., Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422 (2003), 313–317.
4. [4] Park, K.S., Martelotto, L.G., Peifer, M., Sos, M.L., Karnezis, A.N., Mahjoub, M.R., Bernard, K., Conklin, J.F., Szczepny, A., Yuan, J., Guo, R., Ospina, B., Falzon, J., Bennett, S., Brown, T.J., Markovic, A., Devereux, W.L., Ocasio, C.A., Chen, J.K., Stearns, T., Thomas, R.K., Dorsch, M., Buonamici, S., Watkins, D.N., Peacock, C.D., Sage, J., A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat. Med., 2011.
5. [5] Travaglione, V., Peacock, C.D., MacDougall, J., McGovern, K., Cushing, J., Yu, L.C., Trudeau, M., Palombella, V., Adams, J., Hierman, J., Rhodes, J.T., Devereux, W.L., Watkins, D.N., A novel HH pathway inhibitor, IPI-926, delays recurrence post-chemotherapy in a primary human SCLC xenograft model. 99th AACR Annual Meeting, San Diego, CA, 2008, 4611.
6. [6] Watkins, D.N., Berman, D.M., Baylin, S.B., Hedgehog signaling: progenitor phenotype in small-cell lung cancer. Cell Cycle 2 (2003), 196–198.
7. [7] Merchant, A.A., Matsui, W., Targeting Hedgehog—a cancer stem cell pathway. Clin. Cancer Res. 16 (2010), 3130–3140.
8. [8] Dierks, C., Beigi, R., Guo, G.R., Zirlik, K., Stegert, M.R., Manley, P., Trussell, C., Schmitt-Graeff, A., Landwerlin, K., Veelken, H., Warmuth, M., Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14 (2008), 238–249.
9. [9] Zhao, C., Chen, A., Jamieson, C.H., Fereshteh, M., Abrahamsson, A., Blum, J., Kwon, H.Y., Kim, J., Chute, J.P., Rizzieri, D., Munchhof, M., VanArsdale, T., Beachy, P.A., Reya, T., Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458 (2009), 776–779.
10. [10] Liu, S., Dontu, G., Mantle, I.D., Patel, S., Ahn, N.S., Jackson, K.W., Suri, P., Wicha, M.S., Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66 (2006), 6063–6071.
11. [11] Tian, F., Mysliwietz, J., Ellwart, J., Gamarra, F., Huber, R.M., Bergner, A., Effects of the Hedgehog pathway inhibitor GDC-0449 on lung cancer cell lines are mediated by side populations. Clin. Exp. Med. 12 (2012), 25–30.
12. [12] Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D., Verweij, J., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45 (2009), 228–247.
13. [13] Won, H.H., Scott, S.N., Brannon, A.R., Shah, R.H., Berger, M.F., Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. J. Vis. Exp., 2013, e50710.
14. [14] Cheng, D.T., Mitchell, T.N., Zehir, A., Shah, R.H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z.Y., Won, H.H., Scott, S.N., Brannon, A.R., O'Reilly, C., Sadowska, J., Casanova, J., Yannes, A., Hechtman, J.F., Yao, J., Song, W., Ross, D.S., Oultache, A., Dogan, S., Borsu, L., Hameed, M., Nafa, K., Arcila, M.E., Ladanyi, M., Berger, M.F., Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17 (2015), 251–264.
15. [15] Rodon, J., Tawbi, H.A., Thomas, A.L., Stoller, R.G., Turtschi, C.P., Baselga, J., Sarantopoulos, J., Mahalingam, D., Shou, Y., Moles, M.A., Yang, L., Granvil, C., Hurh, E., Rose, K.L., Amakye, D.D., Dummer, R., Mita, A.C., A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin. Cancer Res. 20 (2014), 1900–1909.
16. [16] Migden, M.R., Guminski, A., Gutzmer, R., Dirix, L., Lewis, K.D., Combemale, P., Herd, R.M., Kudchadkar, R., Trefzer, U., Gogov, S., Pallaud, C., Yi, T., Mone, M., Kaatz, M., Loquai, C., Stratigos, A.J., Schulze, H.J., Plummer, R., Chang, A.L., Cornelis, F., Lear, J.T., Sellami, D., Dummer, R., Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 16 (2015), 716–728.
17. [17] Hanna, N., Bunn, P.A. Jr., Langer, C., Einhorn, L., Guthrie, T. Jr., Beck, T., Ansari, R., Ellis, P., Byrne, M., Morrison, M., Hariharan, S., Wang, B., Sandler, A., Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 24 (2006), 2038–2043.
18. [18] Lara, P.N. Jr., Natale, R., Crowley, J., Lenz, H.J., Redman, M.W., Carleton, J.E., Jett, J., Langer, C.J., Kuebler, J.P., Dakhil, S.R., Chansky, K., Gandara, D.R., Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 27 (2009), 2530–2535.
19. [19] Spigel, D.R., Townley, P.M., Waterhouse, D.M., Fang, L., Adiguzel, I., Huang, J.E., Karlin, D.A., Faoro, L., Scappaticci, F.A., Socinski, M.A., Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J. Clin. Oncol. 29 (2011), 2215–2222.
20. [20] Von Hoff, D.D., LoRusso, P.M., Rudin, C.M., Reddy, J.C., Yauch, R.L., Tibes, R., Weiss, G.J., Borad, M.J., Hann, C.L., Brahmer, J.R., Mackey, H., Lum, B.L., Darbonne, W.C., Marsters, J.C., De Sauvage, F.J., Low, J.A., Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. New Engl. J. Med. 361 (2009), 1–9.
21. [21] Rudin, C.M., Hann, C.L., Laterra, J., Yauch, R.L., Callahaun, C.A., Fu, L., Holcomb, T., Stinson, J., Gould, S.E., Coleman, B., LoRusso, P.M., Von Hoff, D.D., De Sauvage, F.J., Low, J.A., Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. New Engl. J. Med. 361 (2009), 1–6.
22. [22] Williams, J.A., Guicherit, O.M., Zaharian, B.I., Xu, Y., Chai, L., Wichterle, H., Kon, C., Gatchalian, C., Porter, J.A., Rubin, L.L., Wang, F.Y., Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 4616–4621.
23. [23] Shou, Y., Robinson, D.M., Amakye, D.D., Rose, K.L., Cho, Y.J., Ligon, K.L., Sharp, T., Haider, A.S., Bandaru, R., Ando, Y., Geoerger, B., Doz, F., Ashley, D.M., Hargrave, D.R., Casanova, M., Tawbi, H.A., Rodon, J., Thomas, A.L., Mita, A.C., MacDonald, T.J., Kieran, M.W., A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin. Cancer Res. 21 (2015), 585–593.
24. [24] Belani, C.P., Dahlberg, S.E., Rudin, C.M., Fleisher, F., Chen, H.X., Takebe, N., Ramalingman, S.S., Schiller, J.H., Three arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib or cixutumumab for patients with extensive stage small cell lung cancer (ECOG1508). J. Clin. Oncol., 31(suppl, abstr 7508), 2013.
25. [25] Justilien, V., Fields, A.P., Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. Clin. Cancer Res. 21 (2015), 505–513.
26. [26] Justilien, V., Walsh, M.P., Ali, S.A., Thompson, E.A., Murray, N.R., Fields, A.P., The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 25 (2014), 139–151.
27. [27] Rudin, C.M., Durinck, S., Stawiski, E.W., Poirier, J.T., Modrusan, Z., Shames, D.S., Bergbower, E.A., Guan, Y., Shin, J., Guillory, J., Rivers, C.S., Foo, C.K., Bhatt, D., Stinson, J., Gnad, F., Haverty, P.M., Gentleman, R., Chaudhuri, S., Janakiraman, V., Jaiswal, B.S., Parikh, C., Yuan, W., Zhang, Z., Koeppen, H., Wu, T.D., Stern, H.M., Yauch, R.L., Huffman, K.E., Paskulin, D.D., Illei, P.B., Varella-Garcia, M., Gazdar, A.F., de Sauvage, F.J., Bourgon, R., Minna, J.D., Brock, M.V., Seshagiri, S., Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44 (2012), 1111–1116.
28. [28] Peifer, M., Fernandez-Cuesta, L., Sos, M.L., George, J., Seidel, D., Kasper, L.H., Plenker, D., Leenders, F., Sun, R., Zander, T., Menon, R., Koker, M., Dahmen, I., Muller, C., Di Cerbo, V., Schildhaus, H.U., Altmuller, J., Baessmann, I., Becker, C., de Wilde, B., Vandesompele, J., Bohm, D., Ansen, S., Gabler, F., Wilkening, I., Heynck, S., Heuckmann, J.M., Lu, X., Carter, S.L., Cibulskis, K., Banerji, S., Getz, G., Park, K.S., Rauh, D., Grutter, C., Fischer, M., Pasqualucci, L., Wright, G., Wainer, Z., Russell, P., Petersen, I., Chen, Y., Stoelben, E., Ludwig, C., Schnabel, P., Hoffmann, H., Muley, T., Brockmann, M., Engel-Riedel, W., Muscarella, L.A., Fazio, V.M., Groen, H., Timens, W., Sietsma, H., Thunnissen, E., Smit, E., Heideman, D.A., Snijders, P.J., Cappuzzo, F., Ligorio, C., Damiani, S., Field, J., Solberg, S., Brustugun, O.T., Lund-Iversen, M., Sanger, J., Clement, J.H., Soltermann, A., Moch, H., Weder, W., Solomon, B., Soria, J.C., Validire, P., Besse, B., Brambilla, E., Brambilla, C., Lantuejoul, S., Lorimier, P., Schneider, P.M., Hallek, M., Pao, W., Meyerson, M., Sage, J., Shendure, J., Schneider, R., Buttner, R., Wolf, J., Nurnberg, P., Perner, S., Heukamp, L.C., Brindle, P.K., Haas, S., Thomas, R.K., Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44 (2012), 1104–1110.
29. [29] Hou, J.M., Greystoke, A., Lancashire, L., Cummings, J., Ward, T., Board, R., Amir, E., Hughes, S., Krebs, M., Hughes, A., Ranson, M., Lorigan, P., Dive, C., Blackhall, F.H., Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am. J. Pathol. 175 (2009), 808–816.
30. [30] Naito, T., Tanaka, F., Ono, A., Yoneda, K., Takahashi, T., Murakami, H., Nakamura, Y., Tsuya, A., Kenmotsu, H., Shukuya, T., Kaira, K., Koh, Y., Endo, M., Hasegawa, S., Yamamoto, N., Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J. Thorac. Oncol. 7 (2012), 512–519.
31. [31] Hou, J.M., Krebs, M.G., Lancashire, L., Sloane, R., Backen, A., Swain, R.K., Priest, L.J., Greystoke, A., Zhou, C., Morris, K., Ward, T., Blackhall, F.H., Dive, C., Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 30 (2012), 525–532.
32. [32] Hiltermann, T.J., Pore, M.M., van den Berg, A., Timens, W., Boezen, H.M., Liesker, J.J., Schouwink, J.H., Wijnands, W.J., Kerner, G.S., Kruyt, F.A., Tissing, H., Tibbe, A.G., Terstappen, L.W., Groen, H.J., Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann. Oncol. 23 (2012), 2937–2942.
33. [33] Hodgkinson, C.L., Morrow, C.J., Li, Y., Metcalf, R.L., Rothwell, D.G., Trapani, F., Polanski, R., Burt, D.J., Simpson, K.L., Morris, K., Pepper, S.D., Nonaka, D., Greystoke, A., Kelly, P., Bola, B., Krebs, M.G., Antonello, J., Ayub, M., Faulkner, S., Priest, L., Carter, L., Tate, C., Miller, C.J., Blackhall, F., Brady, G., Dive, C., Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat. Med. 20 (2014), 897–903.